Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to Insider Trades Newsletter so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.

Baxter International (BAX) Stock Forecast & Price Target

Baxter International logo
$18.78 -0.47 (-2.43%)
Closing price 03:59 PM Eastern
Extended Trading
$18.93 +0.15 (+0.81%)
As of 04:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Baxter International - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
3
Hold
8
Buy
2

Based on 13 Wall Street analysts who have issued ratings for Baxter International in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 13 analysts, 3 have given a sell rating, 8 have given a hold rating, and 2 have given a buy rating for BAX.

Consensus Price Target

$19.73
5.03% Upside
According to the 13 analysts' twelve-month price targets for Baxter International, the average price target is $19.73. The highest price target for BAX is $27.00, while the lowest price target for BAX is $15.00. The average price target represents a forecasted upside of 5.03% from the current price of $18.78.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

BAX Analyst Ratings Over Time

TypeCurrent Forecast
5/29/25 to 5/29/26
1 Month Ago
4/29/25 to 4/29/26
3 Months Ago
2/28/25 to 2/28/26
1 Year Ago
5/29/24 to 5/29/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
5 Buy rating(s)
Hold
8 Hold rating(s)
8 Hold rating(s)
8 Hold rating(s)
3 Hold rating(s)
Sell
3 Sell rating(s)
3 Sell rating(s)
3 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$19.73$19.80$20.10$37.25
Forecasted Upside5.03% Upside17.19% Upside-1.40% Downside21.41% Upside
Consensus RatingReduceReduceReduceHold

BAX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BAX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Baxter International Stock vs. The Competition

TypeBaxter InternationalMedical CompaniesBroader Market
Consensus Rating Score
1.92
2.30
2.52
Consensus RatingReduceHoldModerate Buy
Predicted Upside3.62% Upside1,682.48% Upside14.81% Upside
News Sentiment Rating
Neutral News

See Recent BAX News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
5/28/2026
Citigroup Inc. logo
Citigroup
4 of 5 stars
Joanne Wuensch
Joanne Wuensch
2 of 5 stars
DowngradeNeutralSell$19.00 ➝ $17.00-12.13%
5/25/2026 UpgradeStrong SellHold
5/15/2026 Reiterated RatingSell (E+)
5/1/2026 Lower Target$22.00 ➝ $20.00+15.91%
5/1/2026 Lower Target$20.00 ➝ $19.00+10.11%
5/1/2026 Boost Target$17.00 ➝ $19.00+10.11%
5/1/2026Boost TargetOverweight$25.00 ➝ $27.00+56.48%
4/6/2026 Lower TargetOutperform$23.00 ➝ $22.00+32.09%
2/13/2026 Lower TargetHold$21.00 ➝ $19.00+1.04%
12/12/2025Lower TargetEqual Weight$21.00 ➝ $19.00-0.29%
Trump's gold order: the announcement they won't put on the front page (Ad)

On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel

Request the free guide in 30 seconds and get positioned now
12/2/2025Lower TargetUnderweight$19.00 ➝ $15.00-20.83%
10/31/2025 Lower Target$25.00 ➝ $19.00+2.90%
10/31/2025Lower TargetNeutral$24.00 ➝ $21.00+11.75%
10/31/2025DowngradeBuyHold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 04:46 PM ET.


Should I Buy Baxter International Stock? BAX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, May 28, 2026. Please send any questions or comments about these Baxter International pros and cons to contact@marketbeat.com.

Baxter International
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Baxter International Inc.:

  • The current stock price is around $17.97, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Baxter International Inc. recently reported quarterly earnings that exceeded analysts' expectations, with earnings per share of $0.36 compared to a consensus estimate of $0.31, indicating strong financial performance.
  • The company experienced a year-over-year revenue increase of 2.9%, reflecting growth in demand for its medical products and therapies, which could signal a positive trend for future earnings.
  • Baxter International Inc. has a significant institutional ownership of 90.19%, suggesting strong confidence from large investors in the company's long-term prospects.
  • The firm has a positive return on equity of 15.65%, indicating effective management and profitability relative to shareholder equity, which is a favorable sign for potential investors.

Baxter International
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Baxter International Inc. for these reasons:

  • The company has a negative net margin of 9.70%, which indicates that it is currently spending more than it earns, raising concerns about its profitability.
  • Recent analyst ratings have been mixed, with Zacks Research downgrading the stock to a "strong sell" and other analysts adjusting target prices downward, which may reflect a lack of confidence in the stock's near-term performance.
  • Baxter International Inc. has a relatively high debt-to-equity ratio of 1.55, suggesting that the company is heavily reliant on debt financing, which can be risky in volatile market conditions.
  • The P/E ratio is negative, which can be a red flag for investors as it indicates that the company is not currently generating profits relative to its share price.
  • Despite recent revenue growth, the company posted lower earnings per share compared to the same quarter last year, which may indicate challenges in maintaining profitability moving forward.

BAX Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Baxter International is $19.73, with a high forecast of $27.00 and a low forecast of $15.00.

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Baxter International in the last year. There are currently 3 sell ratings, 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" BAX shares.

According to analysts, Baxter International's stock has a predicted upside of 5.03% based on their 12-month stock forecasts.

Over the previous 90 days, Baxter International's stock had 2 upgrades and 2 downgrades by analysts.

Baxter International has been rated by research analysts at Barclays, Citigroup, Evercore, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, Weiss Ratings, and Zacks Research in the past 90 days.

Analysts like Baxter International less than other "medical" companies. The consensus rating for Baxter International is Reduce while the average consensus rating for "medical" companies is Hold. Learn more on how BAX compares to other companies.


This page (NYSE:BAX) was last updated on 5/29/2026 by MarketBeat.com Staff.
From Our Partners